American Journal of Clinical Pathology · 2005 · 74 citations · 24 references
MedicineOncologyPathologyEndocrine OncologyNeoplasiaTumor PathologyEndocrine Tumor DiagnosisEndocrine Tumor PathologyEndocrine TumorsImmunohistochemistryNeuroendocrine TumorsTumor CharacterizationCrush ArtifactsImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingKi-67 ImmunostainingPulmonary Carcinoid TumorsPulmonary NeoplasmsPulmonary Neuroendocrine Tumors
The aim of the present study was to evaluate the usefulness of immunohistochemical markers in the differential diagnosis of pulmonary neuroendocrine tumors with particular emphasis on the preservation of immunoreactivity in areas showing crush artifacts. Specimens from 9 carcinoid tumors (CTs) and 13 small cell carcinomas (SCCs) with crush artifact were stained with antibodies to Ki-67, chromogranin A, synaptophysin, and cytokeratin. The immunoreactivity was well preserved in the crushed areas. Ki-67 was expressed in the crushed areas of all SCCs. Reactivity was diffuse or at least present in 25% of the crushed areas. In contrast, the immunoreactive areas in CTs never exceeded 10%. Immunoreactivity for Ki-67, synaptophysin, chromogranin A, and cytokeratin is well preserved in tissue with crush artifacts and can be interpreted reliably. The diagnosis of SCC should be questioned if fewer than 25% of cells show reactivity for Ki-67.
24
Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.
Élisabeth Brambilla, A Negoescu, Sylvie Gazzéri et al. · PubMed · 1996 · 274 citations
Oat‐cell carcinoma of the bronchus
J. G. Azzopardi · The Journal of Pathology and Bacteriology · 1959 · 235 citations
Genetic changes in the spectrum of neuroendocrine lung tumors
Naoyoshi Onuki, Ignacio I. Wistuba, William D. Travis et al. · Cancer · 1999 · 224 citations